Bezpečnost dlouhodobé léčby filgrastimem v dávce nad 2, 4 MIU (24 μg) / kg/ den u pacientů s SCN nebyla stanovena.
The long-term safety of filgrastim administration above 2.4 MIU (24 μ g)/ kg/ day in patients with SCN has not been established.